DESCRIPTION:

List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Prostate cancer aggressiveness. The EFO term cancer aggressiveness measurement, Gleason score measurement, prostate carcinoma was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.

LABEL:

GWAS: cancer aggressiveness measurement, Gleason score measurement, prostate carcinoma

SCORE TYPE:

P-Value

DATE ADDED:

2017-05-02

DATE UPDATED:

2024-04-25

SPECIES:

AUTHORS:

SI Berndt, Z Wang, M Yeager, MC Alavanja, D Albanes, L Amundadottir, G Andriole, L Beane Freeman, D Campa, G Cancel-Tassin, F Canzian, JN Cornu, O Cussenot, WR Diver, SM Gapstur, H Grönberg, CA Haiman, B Henderson, A Hutchinson, DJ Hunter, TJ Key, S Kolb, S Koutros, P Kraft, L Le Marchand, S Lindström, MJ Machiela, EA Ostrander, E Riboli, F Schumacher, A Siddiq, JL Stanford, VL Stevens, RC Travis, KK Tsilidis, J Virtamo, S Weinstein, F Wilkund, J Xu, S Lilly Zheng, K Yu, W Wheeler, H Zhang, J Sampson, A Black, K Jacobs, RN Hoover, M Tucker, SJ Chanock

TITLE:

Two susceptibility loci identified for prostate cancer aggressiveness.

JOURNAL:

Nature communications May 2015, Vol 6, pp. 6889

ABSTRACT:

Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10(-9)) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10(-8)). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10(-5)) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation. PUBMED: 25939597
Find other GeneSets from this publication